Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target
07:56am, Friday, 13'th Feb 2026
Moderna said it continues to target 10% revenue growth this year, as the company's fourth-quarter loss narrowed from a year earlier.
First Look: Tech-led selloff, tariff shifts, AI funding boom
07:38am, Friday, 13'th Feb 2026
Stock News Tech slump hits indexes: A broad risk-off move saw Apple (AAPL) and Cisco (CSCO) lead declines, while Applied Materials (AMAT) rallied on upbeat AI t
Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.
07:13am, Friday, 13'th Feb 2026
Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.
Moderna beats fourth-quarter revenue estimates
07:06am, Friday, 13'th Feb 2026
Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.
Moderna shares pop on strong guidance, smaller-than-expected loss
07:03am, Friday, 13'th Feb 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday....
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
07:00am, Friday, 13'th Feb 2026
Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) Reports full-year revenue of $1.9 billion, GAAP net loss of $(2.8) billion and GAAP diluted EPS
Moderna Stock Sports Technical Support Ahead Of Earnings
03:25pm, Thursday, 12'th Feb 2026
Pharma stock Moderna (MRNA) is experiencing a sharp pullback from its Jan. 22, 52-week high of $55.20. Last seen down 3.5% at $39.08, the shares are headed for their third-straight weekly loss.
Moderna: Stock to Avoid or Bad News Buy?
11:10am, Thursday, 12'th Feb 2026
Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won't review the biotech's flu vaccine candidate.
First Look: McDonald's beats, Hims sued, WBD deal battle
07:39am, Thursday, 12'th Feb 2026
Stock News Futures edge up as jobs data and earnings mix: U.S. stock futures inched higher after January payrolls rose 130,000 with unemployment at 4.3%, compli
Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader
07:27am, Thursday, 12'th Feb 2026
Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector's 0.4% YTD return.
Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?
05:10am, Thursday, 12'th Feb 2026
The U.S. Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the l
The head of the agency's vaccine division, Vinay Prasad, has overruled pushback from career staffers.
Market Today: Jobs Beat Sways Stocks; MCD, WBD in Focus
05:36pm, Wednesday, 11'th Feb 2026
Guru Stock PicksCatherine Wood has made the following transactions:Reduce in NXDR by 2.41%Sold out in KMDAAdd in FVRR by 24%New position in IWBPRIMECAP Manageme
FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'
03:15pm, Wednesday, 11'th Feb 2026
The new shot was not compared to “the best-available standard of care in the United States at the time of the study,” an FDA official told Moderna.
Moderna's investigational flu vaccine denied FDA review, shares drop
01:03pm, Wednesday, 11'th Feb 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares fell almost 6% after the drugmaker announced that the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has issue
